We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 590

Pharmaceuticals and Brexit: Keeping the industry healthy
  • Linklaters LLP
  • United Kingdom, European Union
  • June 19 2018

It is estimated that each month 37 million packs of medicines are supplied from European countries to the UK with 45 million heading in the other

Life Sciences International Review Q2 2018
  • Morgan Lewis & Bockius LLP
  • USA, United Kingdom, European Union, France
  • June 6 2018

The most-significant recent development is the entry into force on 25 May of the EU General Data Protection Regulation. This new legislation will have

How do you protect the IP of 3D printed drugs and medical devices?
  • Marks & Clerk
  • USA, United Kingdom
  • February 15 2018

3D printing - also known as additive manufacturing - is set to revolutionise a large number of industries, allowing for innovative product designs and

UK retailers remove baby sleep positioners from sale
  • Leigh Day
  • United Kingdom
  • October 9 2017

Leading UK retailers have halted the sale of baby sleep positioners following a warning from the US Food and Drug Administration, the FDA, that the

UK MHRA Issues New Guidance on Human Factors and Usability Engineering for Medical Devices
  • Hogan Lovells
  • United Kingdom, European Union
  • September 22 2017

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance on taking human factors into account when designing

New FDA Final Guidance on Medical Device Panel Meetings Provides Certain Changes to Timelines and Procedures
  • Hogan Lovells
  • United Kingdom
  • September 20 2017

On September 1, 2017, the Food and Drug Administration (FDA or the Agency) released a final guidance document discussing the procedures for Medical

FDA approves first GM individualised Cell Therapy
  • Bristows LLP
  • United Kingdom
  • September 20 2017

Novartis has received FDA approval for its CAR-T cell therapy, marketed as Kymriah, for the treatment of a particular type of blood cancer, acute

"Miracle Gel" Not a Salon Gel Manicure, Ad Board Says
  • Shook Hardy & Bacon LLP
  • USA, United Kingdom, European Union
  • August 30 2017

In an appeal from a ruling by the National Advertising Division (NAD), the National Advertising Review Board (NARB) upheld a recommendation that Coty

Is there such a thing as Substitution or Interchangeability for Biosimilars?
  • Bristows LLP
  • United Kingdom
  • August 11 2017

Biological medicinal products have rapidly become one of the fastest growing areas of medicine and for many conditions they offer a new and more

Essure, the alternative to tubal ligation for UK women, to be discontinued in September 2017
  • Leigh Day
  • USA, United Kingdom, Canada
  • June 21 2017

The German multinational chemical and pharmaceutical company Bayer AG have confirmed several changes to the supply and distribution of the Essure